Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with ...

Corporation, a biopharmaceutical company specializing in proprietary therapeutics with a market capitalization of $14 billion ...

Last year, Incyte became the first pharma company to get approval for a drug that can re-pigment the skin in vitiligo – topical JAK1/JAK2 inhibitor Opzelura (ruxolitinib) – for patients whose ...

Combining baricitinib with narrowband UVB phototherapy led to significant repigmentation and enhanced quality of life in ...

Galapagos (0JXZ – Research Report) received a Sell rating and a €22.00 price target from Barclays analyst Emily Field today. The company’s ...

Andrew Kuykendall, MD, discusses the rationale behind choosing to evaluate fedratinib in a phase 2 study for patients with atypical chronic myeloid leukemia, chronic neutrophilic leukemia, ...

The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune diseases.

Recent clinical trials have shown promising results for JAK inhibitors in treating alopecia areata. For instance, two phase 3 trials of baricitinib, a selective JAK1 and JAK2 inhibitor ...

Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. It has a plasma elimination half-life of 12 hours and has been administered in a twice-daily dosing ...